# EDGAR Filing Document

**Accession Number:** 0002038166
**File Stem:** 0001213900-26-064632
**Filing Date:** 2026-6
**Character Count:** 2249
**Document Hash:** 39fef797bcd39e61d886a785ec5cde04
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-064632.hdr.sgml**: 20260603

**ACCESSION NUMBER**: 0001213900-26-064632

**CONFORMED SUBMISSION TYPE**: 1-U

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260528

**ITEM INFORMATION**: Departure of Certain Officers

**FILED AS OF DATE**: 20260603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nok Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002038166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 993344253
- **STATE OF INCORPORATION:** FL

**FILING VALUES:**
- **FORM TYPE:** 1-U
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 24R-00991
- **FILM NUMBER:** 261060170

**BUSINESS ADDRESS:**
- **STREET 1:** 1452 N US HIGHWAY 1
- **STREET 2:** STE 123
- **CITY:** ORMOND BEACH
- **STATE:** FL
- **ZIP:** 32174
- **BUSINESS PHONE:** 888-645-3947

**MAIL ADDRESS:**
- **STREET 1:** 1452 N US HIGHWAY 1
- **STREET 2:** STE 123
- **CITY:** ORMOND BEACH
- **STATE:** FL
- **ZIP:** 32174

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 1-U**

**CURRENT REPORT PURSUANT TO REGULATION A**

Date of Report (Date of earliest event reported) May 28, 2026

NOK Therapeutics, Inc.

<u>Florida</u> <u>99-3344253</u>

2009 MacKenzie Way, Suite 100

Cranberry Township, Pennsylvania 16066

888-691-5839

Title of each class of securities issued pursuant to Regulation A:

<u>Common Stock</u>

Item 7. Departure of Certain Officers

On May 28, 2026, Robert Lewis, President and Principal Executive Officer, stepped down from his position as President and Director of NOK Therapeutics, Inc., effective immediately.

Mr. Lewis's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| (Exact name of issuer as specified in its charter) | NOK Therapeutics, Inc. |
|  | /s/ *Brian Cogley* |
| By (Signature and Title) | Brian Cogley |
|  | Chief Financial Officer |
| Date: June 3, 2026 |  |

---